Could This News Change Everything for Moderna?
Moderna (NASDAQ: MRNA) investors and potential investors have one big worry these days: that the company's billion-dollar coronavirus vaccine sales may drop. About 67% of the U.S. population now is fully vaccinated. So the concern is major demand for the company's vaccine may be over.
As a result, demand for Moderna stock has declined. The shares have slipped more than 35% so far this year. But there's a sign investors' concerns may be overdone. And that's a new billion-dollar vaccine order from the United States. Could this news change everything for Moderna? Let's find out.
First, some details about the order. The U.S. signed up for an initial 66 million doses. This isn't for the original coronavirus vaccine. Instead, it's for Moderna's new booster candidate targeting the original coronavirus and the omicron BA.4 and BA.5 strain.
Source Fool.com